{"id":"placebo-matching-depemokimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL4650469","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Depemokimab blocks IL-4Rα signaling, which is a key driver of type 2 inflammation involving Th2 cells, eosinophils, and IgE production. By inhibiting this pathway, the drug reduces eosinophilic and allergic inflammatory responses. This mechanism is relevant to eosinophilic and allergic diseases where IL-4Rα-mediated signaling plays a central pathogenic role.","oneSentence":"Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:51.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eosinophilic esophagitis"},{"name":"Eosinophilic gastritis"}]},"trialDetails":[{"nctId":"NCT07177339","phase":"PHASE3","title":"eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1196},{"nctId":"NCT05334368","phase":"PHASE3","title":"Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-09-06","conditions":"Hypereosinophilic Syndrome","enrollment":123},{"nctId":"NCT05263934","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-07-14","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":163},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT04719832","phase":"PHASE3","title":"Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-03-17","conditions":"Asthma","enrollment":395}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching depemokimab","genericName":"Placebo matching depemokimab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses. Used for Eosinophilic esophagitis, Eosinophilic gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}